Acasti Pharma Q4 Adj EPS $(0.11), Inline, Cash Balance Of $27.9M
Portfolio Pulse from Benzinga Newsdesk
Acasti Pharma reported Q4 losses of $(0.95) per share, a 2275% decrease from $(0.04) YoY. The company's cash balance stands at $27.9 million, down from $43.7 million last year.
June 23, 2023 | 11:47 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Acasti Pharma's Q4 losses increased significantly to $(0.95) per share, and its cash balance decreased to $27.9 million.
Acasti Pharma's Q4 earnings report shows a significant increase in losses and a decrease in cash balance. This negative financial performance may lead to short-term pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100